| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | CH5424802 | GDSC1000 | pan-cancer | AAC | 0.31 | 3e-20 |
| mRNA | MPS-1-IN-1 | GDSC1000 | pan-cancer | AAC | 0.23 | 2e-13 |
| mRNA | TAE684 | GDSC1000 | pan-cancer | AAC | 0.33 | 2e-10 |
| mRNA | TAE684 | CTRPv2 | pan-cancer | AAC | 0.22 | 4e-10 |
| mRNA | BHG712 | GDSC1000 | pan-cancer | AAC | -0.16 | 4e-08 |
| mRNA | Rapamycin | CTRPv2 | pan-cancer | AAC | 0.18 | 1e-07 |
| mRNA | XMD15-27 | GDSC1000 | pan-cancer | AAC | 0.18 | 2e-07 |
| mRNA | TAE684 | CCLE | pan-cancer | AAC | 0.23 | 1e-06 |
| mRNA | tipifarnib | CTRPv2 | pan-cancer | AAC | 0.15 | 1e-06 |
| mRNA | sirolimus:bortezomib (250:1 mol/mol) | CTRPv2 | pan-cancer | AAC | 0.16 | 2e-06 |